• By Concept
  • By Last Name
  • By Full Text

Hyman, Bradley T

Grant Detail

The grant detail shows the name of the PI, active dates of the project, the funding institute and the abstract of the grant. This abstract is what is used to create the fingerprint of the grant. If any publications referencing this grant are found in the data, they will be listed here as well.



Gamma Secretases in Alzheimers Disease

Golde, Todd E

10 April 2000 - 30 April 2009
NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE
Total Funding: $ 2,532,291

FY 2008
5R01NS039072-08
$ 320,011
FY 2007
5R01NS039072-07
$ 320,011
FY 2006
5R01NS039072-06
$ 329,569
FY 2005
5R01NS039072-05
$ 337,500
FY 2004
2R01NS039072-04A2
$ 312,500
FY 2002
5R01NS039072-03
$ 306,000
FY 2001
5R01NS039072-02
$ 306,000
FY 2000
1R01NS039072-01A1
$ 300,700
 
 
$ 2,532,291
Abstract

Gamma-secretase catalyzes the final cleavage that releases ABeta from its precursor; therefore, it is a potential therapeutic target for the treatment of AD. A great deal of evidence now supports the concept that presenilins (PS) are catalytic components of the high molecular weight gamma-secretase complex. We have identified a novel family of presenilin homologues (PSH). PSH can be aligned over most of their lengths with PS. Regions that are highly conserved between the two families include i) putative active site aspartate residues in TMD6 and TMD7, ii) TMD sequences in general, and iii) a 'PAL' motif that is reported to be obligatory for stabilization, complex formation, and gamma-secretase activities of PS. One of the PSH has now been shown to be an intramembrane cleaving protease. Based on this evidence we hypothesize that that PS and PSH represent a family of intramembraneous cleaving proteases with a conserved catalytic mechanism. As shown for other enzyme families, the identification of a wider repertoire of PS/PSH family members may now facilitate a greater understanding of the molecular and cellular functions of this biomedically-important family. Given the interest in developing gamma-secretase inhibitors that target PS as potential therapeutic agents, information gathered by studying this protein family may offer important insights into the potential catalytic mechanisms and substrate-specificities of PS and PSH that will aid the development of such inhibitors. These studies will also provide general insight as to how intramembrane cleavage of peptide bonds occurs. The questions we will address are 1) What are the basic characteristics and cellular roles of the PSH proteins? 2) Do PSs and PSHs utilize a catalytic mechanism similar to that known of other aspartyl proteases? 3) What are the structural similarities between the active sites of PSH and PS? Do PSHs possess an initial substrate docking site as PS apparently does? And 4) Does SPP/PSH3 indeed act alone (and as a dimer)?

15 Resulting Publications

Scientific Context

This section shows information that has been computed by using the fingerprint of the grant, including related publications, related experts and related grants - all with fingerprints representing significant amounts of overlap between their fingerprint and this grant. The red dots indicate whether those experts or terms actually appear within this grant, showing potential and actual connections.

Related Grants

Related Publications